Participation in Roth Conference and Other Matters (2059Z)
March 13 2012 - 3:01AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 2059Z
Medgenics Inc
13 March 2012
Press Release 13 March 2012
MEDGENICS Announces Participation in Roth Conference and Other
Matters
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the
developer of a novel technology for the sustained production and
delivery of therapeutic proteins in patients using their own
tissue, today announced that Andrew L. Pearlman, Ph.D., President
and Chief Executive Officer of the Company, will deliver a
corporate overview at the 24(th) Annual Roth Conference taking
place March 11-14(th) at the Ritz Carlton in Dana Point,
California. Dr. Pearlman will deliver his presentation on March
14(th) at 10:30 a.m. Pacific time.
The presentation will be webcast live and archived online at the
Investors section of the Company's website at www.medgenics.comand
at http://wsw.com/webcast/roth26/mdgn/.
The Company also reported that, consistent with its prior
financial statements, its audited financial statements for the
fiscal year ended December 31, 2011 included in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 6, 2012 contained a going concern qualification
from its independent registered public accounting firm, Kost Forer
Gabbay & Kasierer, a member of Ernst & Young Global. This
announcement is in compliance with the NYSE Amex Company Guide
Section 610(b), which requires separate disclosure of receipt of an
audit opinion containing a going concern qualification. Medgenics
continues as a development stage company, pursuing the development
and commercialization of its Biopump(TM) Platform Technology,
having expended $6.0 million on research and development during
fiscal 2011. This announcement does not represent any change or
amendment to the Company's consolidated financial statements or to
its Annual Report on Form 10-K for the fiscal year ended December
31, 2011. Further information regarding the going concern
qualification is contained in Medgenics' Annual Report on Form 10-K
for the year ended December 31, 2011.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia. Medgenics believes
this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE (now completing a Phase I/II dose-ranging trial) to
produce and deliver erythropoietin for many months from a single
administration, has demonstrated elevation and stabilization of
hemoglobin levels in anemic patients for six to more than 36
months;
-- INFRADURE (planning to commence a Phase I/II trial in Israel
in 1H12 in hepatitis C) to produce a sustained therapeutic dose of
interferon-alpha for use in the treatment of hepatitis;
-- HEMODURE is a sustained Factor VIII therapy for the
prophylactic treatment of hemophilia, now in development.
Medgenics intends to develop its innovative products and bring
them to market via strategic partnerships with major pharmaceutical
and/or medical device companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump(TM) products targeting the large and rapidly growing global
protein therapy market, which is forecast to reach $132 billion in
2013. Other potential applications for Biopumps(TM) include
multiple sclerosis, arthritis, pediatric growth hormone deficiency,
obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
andrew.pearlman@medgenics.com
LHA Phone: 212-838-3777
Anne Marie Fields
afields@lhai.com
@LHA_IR_PR
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Religare Capital Markets (NOMAD) Phone: +44 207 444 0800
Emily Staples
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
Nomura Code Securities (Joint Broker) Phone: +44 207 776 1219
Jonathan Senior
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFFFUEFESEID
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024